W. Boyle, W. Simonet, and D. Lacey, Osteoclast differentiation and activation, Nature, vol.20, issue.Suppl., pp.337-342, 2003.
DOI : 10.1007/s007740200049

M. Asagiri and H. Takayanagi, The molecular understanding of osteoclast differentiation, Bone, vol.40, issue.2, pp.251-264, 2007.
DOI : 10.1016/j.bone.2006.09.023

D. Biskobing, X. Fan, and R. J. , Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture, Journal of Bone and Mineral Research, vol.134, issue.7, pp.1025-1032, 1995.
DOI : 10.1101/SQB.1988.053.01.060

F. Arai, T. Miyamoto, O. Ohneda, T. Inada, and T. Sudo, Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor ??b (Rank) Receptors, The Journal of Experimental Medicine, vol.21, issue.12, pp.1741-1754, 1999.
DOI : 10.1084/jem.177.1.237

S. Wei, S. Teitelbaum, M. Wang, and F. Ross, Endocrinology, vol.142, issue.3, pp.1290-1295, 2001.
DOI : 10.1210/endo.142.3.8031

M. Matsumoto, T. Sudo, T. Saito, H. Osada, and M. Tsujimoto, Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-??B Ligand (RANKL), Journal of Biological Chemistry, vol.16, issue.40, pp.31155-31161, 2000.
DOI : 10.1128/MCB.16.3.1247

J. David, K. Sabapathy, O. Hoffmann, M. Idarraga, and E. Wagner, JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms, Journal of Cell Science, vol.115, issue.22, pp.4317-4325, 2002.
DOI : 10.1242/jcs.00082

S. Lee, K. Woo, S. Kim, H. Kim, and K. Kwack, The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation, Bone, vol.30, issue.1, pp.71-77, 2002.
DOI : 10.1016/S8756-3282(01)00657-3

V. Iotsova, J. Caamano, J. Loy, Y. Yang, and A. Lewin, Osteopetrosis in mice lacking NF-??B1 and NF-??B2, Nature Medicine, vol.266, issue.11, pp.1285-1289, 1997.
DOI : 10.1038/386081a0

D. Novack, Role of NF-??B in the skeleton, Cell Research, vol.171, issue.1, pp.169-182, 2011.
DOI : 10.1158/1541-7786.MCR-08-0108

G. Franzoso, L. Carlson, L. Xing, L. Poljak, and E. Shores, Requirement for NF-kappa B in osteoclast and B-cell??development, Genes & Development, vol.11, issue.24, pp.3482-3496, 1997.
DOI : 10.1101/gad.11.24.3482

M. Asagiri, K. Sato, T. Usami, S. Ochi, and H. Nishina, Autoamplification of NFATc1 expression determines its essential role in bone homeostasis, The Journal of Experimental Medicine, vol.96, issue.9, pp.1261-1269, 2005.
DOI : 10.1007/s00109-004-0612-6

H. Takatsuna, M. Asagiri, T. Kubota, K. Oka, and T. Osada, Inhibition of RANKL-Induced Osteoclastogenesis by (???)-DHMEQ, a Novel NF-??B Inhibitor, Through Downregulation of NFATc1, Journal of Bone and Mineral Research, vol.10, issue.Suppl 1, pp.653-662, 2005.
DOI : 10.4049/jimmunol.171.10.5547

A. Grigoriadis, Z. Wang, M. Cecchini, W. Hofstetter, and R. Felix, c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling, Science, vol.266, issue.5184, pp.443-448, 1994.
DOI : 10.1126/science.7939685

F. Ikeda, T. Matsubara, T. Tsurukai, K. Hata, and R. Nishimura, JNK/c-Jun Signaling Mediates an Anti-Apoptotic Effect of RANKL in Osteoclasts, Journal of Bone and Mineral Research, vol.156, issue.6, pp.907-914, 2008.
DOI : 10.1016/S0002-9440(10)64967-X

H. Takayanagi, The Role of NFAT in Osteoclast Formation, Annals of the New York Academy of Sciences, vol.1116, issue.1, pp.227-237, 2007.
DOI : 10.1196/annals.1402.071

Y. Arai, S. Watanabe, M. Kimira, K. Shimoi, and R. Mochizuki, Dietary Intakes of Flavonols, Flavones and Isoflavones by Japanese Women and the Inverse Correlation between Quercetin Intake and Plasma LDL Cholesterol Concentration, The Journal of Nutrition, vol.88, issue.9, 2000.
DOI : 10.1172/JCI115499

, J Nutr, vol.130, pp.2243-2250

N. Khan, M. Asim, F. Afaq, A. Zaid, M. Mukhtar et al., A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude Mice, Cancer Research, vol.68, issue.20, pp.8555-8563, 2008.
DOI : 10.1158/0008-5472.CAN-08-0240

P. Maher, T. Akaishi, and K. Abe, Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory, Proceedings of the National Academy of Sciences, vol.16, issue.3, pp.16568-16573, 2006.
DOI : 10.1517/13543784.11.1.1

P. Maher, R. Dargusch, L. Bodai, P. Gerard, and J. Purcell, ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease, Human Molecular Genetics, vol.87, issue.2, pp.261-270, 2011.
DOI : 10.1016/S0092-8674(00)81369-0

J. Lee, J. Huh, G. Jeon, H. Yang, and H. Woo, Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models, International Immunopharmacology, vol.9, issue.3, pp.268-276, 2009.
DOI : 10.1016/j.intimp.2008.11.005

S. Liu, C. Lin, S. Hung, J. Chou, and C. Chi, Fisetin Inhibits Lipopolysaccharide-Induced Macrophage Activation and Dendritic Cell Maturation, Journal of Agricultural and Food Chemistry, vol.58, issue.20, 2010.
DOI : 10.1021/jf1017093

G. Mundy, Osteoporosis and Inflammation, Nutrition Reviews, vol.65, issue.12, pp.147-151, 2007.
DOI : 10.1301/nr.2007.dec.S147-S151

K. Redlich and J. Smolen, Inflammatory bone loss: pathogenesis and therapeutic intervention, Nature Reviews Drug Discovery, vol.26, issue.3, pp.234-250, 2012.
DOI : 10.1002/jbmr.212

H. Hsu, D. Lacey, C. Dunstan, I. Solovyev, and A. Colombero, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proceedings of the National Academy of Sciences, vol.273, issue.43, pp.3540-3545, 1999.
DOI : 10.1074/jbc.273.43.28355

L. Leotoing, F. Chereau, S. Baron, F. Hube, and H. Valencia, A20-binding Inhibitor of Nuclear Factor-??B (NF-??B)-2 (ABIN-2) Is an Activator of Inhibitor of NF-??B (I??B) Kinase ?? (IKK??)-mediated NF-??B Transcriptional Activity, Journal of Biological Chemistry, vol.13, issue.37, pp.32277-32288, 2011.
DOI : 10.1158/1078-0432.CCR-10-1859

Y. Gao, F. Grassi, M. Ryan, M. Terauchi, and K. Page, IFN-?? stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation, Journal of Clinical Investigation, vol.117, issue.1, pp.122-132, 2007.
DOI : 10.1172/JCI30074

M. Billard, A. Gruver, and G. Sempowski, Acute Endotoxin-Induced Thymic Atrophy Is Characterized By Intrathymic Inflammatory and Wound Healing Responses, PLoS ONE, vol.21, issue.3, p.17940, 2011.
DOI : 10.1371/journal.pone.0017940.s011

T. Wada, T. Nakashima, N. Hiroshi, and J. Penninger, RANKL???RANK signaling in osteoclastogenesis and bone disease, Trends in Molecular Medicine, vol.12, issue.1, pp.17-25, 2006.
DOI : 10.1016/j.molmed.2005.11.007

T. Boutros, E. Chevet, and P. Metrakos, Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer, Pharmacological Reviews, vol.60, issue.3, pp.261-310, 2008.
DOI : 10.1124/pr.107.00106

A. Lawan, H. Shi, F. Gatzke, and A. Bennett, Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions, Cellular and Molecular Life Sciences, vol.102, issue.5, 2012.
DOI : 10.1002/ijc.10746

D. Finley, Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome, Annual Review of Biochemistry, vol.78, issue.1, pp.477-513, 2009.
DOI : 10.1146/annurev.biochem.78.081507.101607

R. Rizzoli and J. Reginster, Adverse drug reactions to osteoporosis treatments, Expert Review of Clinical Pharmacology, vol.377, issue.5, pp.593-604, 2011.
DOI : 10.1016/S0140-6736(10)62349-5

S. Khosla, J. Bilezikian, D. Dempster, E. Lewiecki, and P. Miller, Benefits and Risks of Bisphosphonate Therapy for Osteoporosis, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.7, pp.2272-2282, 2012.
DOI : 10.1210/jc.2012-1027

K. Brown, Is tamoxifen a genotoxic carcinogen in women?, Mutagenesis, vol.19, issue.3, pp.391-404, 2009.
DOI : 10.1021/tx0503045

R. Zand, D. Jenkins, and E. Diamandis, Steroid hormone activity of flavonoids and related compounds, Breast Cancer Research and Treatment, vol.146, issue.1, pp.35-49, 2000.
DOI : 10.1093/oxfordjournals.aje.a009270

V. Breinholt and J. Larsen, Detection of Weak Estrogenic Flavonoids Using a Recombinant Yeast Strain and a Modified MCF7 Cell Proliferation Assay, Chemical Research in Toxicology, vol.11, issue.6, pp.622-629, 1998.
DOI : 10.1021/tx970170y

F. Goh, N. Upton, S. Guan, C. Cheng, and M. Shanmugam, Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-??B, European Journal of Pharmacology, vol.679, issue.1-3, pp.109-116, 2012.
DOI : 10.1016/j.ejphar.2012.01.002

L. Geraets, A. Haegens, K. Brauers, J. Haydock, and J. Vernooy, Inhibition of LPS-induced pulmonary inflammation by specific flavonoids, Biochemical and Biophysical Research Communications, vol.382, issue.3, pp.598-603, 2009.
DOI : 10.1016/j.bbrc.2009.03.071

B. Sung, M. Pandey, and B. Aggarwal, Fisetin, an Inhibitor of Cyclin-Dependent Kinase 6, Down-Regulates Nuclear Factor-??B-Regulated Cell Proliferation, Antiapoptotic and Metastatic Gene Products through the Suppression of TAK-1 and Receptor-Interacting Protein-Regulated I??B?? Kinase Activation, Molecular Pharmacology, vol.71, issue.6, pp.1703-1714, 2007.
DOI : 10.1124/mol.107.034512

S. Choi, Y. Son, J. Yun, and S. Kim, Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways, Evidence-Based Complementary and Alternative Medicine, vol.273, issue.5279, p.810563, 2012.
DOI : 10.1074/jbc.M408795200

URL : http://doi.org/10.1155/2012/810563

E. Sakai, M. Shimada-sugawara, Y. Yamaguchi, H. Sakamoto, and R. Fumimoto, Fisetin Inhibits Osteoclastogenesis Through Prevention of RANKL-Induced ROS Production by Nrf2-Mediated Up-regulation of Phase II Antioxidant Enzymes, Journal of Pharmacological Sciences, vol.121, issue.4, pp.288-298, 2013.
DOI : 10.1254/jphs.12243FP

C. Chien, K. Shen, J. Huang, S. Ko, and Y. Shih, Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells, Molecular and Cellular Biochemistry, vol.61, issue.1-2, pp.169-180, 2010.
DOI : 10.1042/bj3360599

, Fisetin Promotes Bone Health PLOS ONE | www.plosone.org

L. Wancket, W. Frazier, and Y. Liu, Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease, Life Sciences, vol.90, issue.7-8, pp.237-248, 2012.
DOI : 10.1016/j.lfs.2011.11.017

J. Carlson, W. Cui, Q. Zhang, X. Xu, and F. Mercan, Role of MKP-1 in Osteoclasts and Bone Homeostasis, The American Journal of Pathology, vol.175, issue.4, pp.1564-1573, 2009.
DOI : 10.2353/ajpath.2009.090035

C. Mahalingam, T. Datta, R. Patil, J. Kreider, and R. Bonfil, Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone, Journal of Endocrinology, vol.16, issue.7, pp.145-156, 2011.
DOI : 10.1359/jbmr.2001.16.7.1300

J. Brondello, J. Pouyssegur, and F. Mckenzie, Reduced MAP Kinase Phosphatase-1 Degradation After p42/p44MAPK-Dependent Phosphorylation, Science, vol.286, issue.5449, pp.2514-2517, 1999.
DOI : 10.1126/science.286.5449.2514